Blog

NEW YORK, NY / ACCESS Newswire / November 6, 2025 / There’s a difference between saying and showing. Between talking about change and proving it happened. For decades, the sustainability movement has been powered by optimism, slogans, and moral urgency. But somewhere along the way, the language of progress got tangled in the politics of promises. SMX (NASDAQ:SMX) has stepped in to take the conversation to the next level. And it only requires a single word to describe how: PROOF.

When Rolling Stone declared that plastic promises are dead and proof is the new flex, it didn’t sound like just another environmental feature – it felt like a reckoning. The magazine that spent half a century defining culture had just defined the next era of commerce. Proof, not pledges, is now the currency of trust.

And that shift isn’t isolated to one outlet. From USA Today to The Straits Times, Morning Honey, OPIS, and The Los Angeles Tribune, a global media chorus is aligning on a single theme: SMX isn’t selling sustainability. It’s verifying it with PROOF.

Proof Has Replaced Faith

SMX’s molecular marking technology operates like a truth serum for the material world. It embeds a digital memory inside plastics, rubber, textiles, metals, and electronics, giving each item a verifiable identity that stays intact through recycling, reuse, and resale. That means every piece of matter – from a soda bottle to a smartphone component – can now tell its own story, backed by science.

The result is a circular economy that no longer runs on declarations or audits. It runs on data. SMX’s technology makes it possible to know, not assume, where a product came from, how it was made, and whether it truly re-entered the supply chain. It’s sustainability without the guesswork – a blueprint for measurable accountability.

USA Today captured this transformation in plain language: the global supply chain is being rebuilt around verifiable data. Every shipment, every material, every recycled input can now carry its own identity. That shift doesn’t just make reporting cleaner; it eliminates the loopholes that once allowed greenwashing to thrive. For corporations, the new reality is simple – accountability is no longer optional. It’s built in.

From Policy to Pop Culture

The validation isn’t just industrial – it’s international. The Straits Times spotlighted Singapore’s national framework for a plastics passport, a program developed in collaboration with A*STAR and powered by SMX’s molecular markers. The system lets products carry digital proof of origin and composition, extending the lifespan of materials and reshaping how recycling is tracked across ASEAN.

Meanwhile, OPIS covered SMX’s work in Asia-Pacific, adding to the value of its partnerships with CARTIF in Spain and CETI in France, two of the region’s leading innovation hubs. CARTIF is using SMX’s technology to help European industries meet new circular-economy reporting mandates, while CETI is embedding molecular IDs into fibers and fabrics, turning recycled-textile claims into verifiable data points. Sourcing Journal even followed SMX’s trail into luxury fashion, where its molecular markers are being used in lambskin and leather to validate ethical sourcing.

In Austria, REDWAVE is bringing the technology to the factory floor, integrating SMX markers into its industrial sorters to verify recycled materials in real time. In the United States, Tradepro is closing the loop by distributing certified recycled resin that carries SMX’s proof-of-signature to manufacturers under strict compliance targets.

Even the gold standard is being rewritten. Singapore-based Goldstrom is deploying SMX’s molecular marker to give precious metals a permanent digital identity, allowing banks, refiners, and traders to verify authenticity across their entire supply chain. It’s an unprecedented step for the metals market – proof where trust once relied on stamps and paper trails.

Together, these six 2025 partnerships – A*STAR, CETI, CARTIF, REDWAVE, Tradepro, and Goldstrom – form the world’s first cross-sector network of verified commerce. Proof isn’t siloed anymore; it’s global. Morning Honey captured that cultural shift, showing how SMX’s traceability technology connects sustainability, consumer fairness, and global trade. And The Los Angeles Tribune distilled the financial impact into one line: “Carbon Credits Had Their Day.” Their replacement? SMX’s Plastic Cycle Token (PCT), a blockchain-backed proof instrument that turns verified recycled content into a tradable digital asset.

The Market Has Spoken

All told, proof isn’t a slogan anymore. It’s infrastructure. It links regulation, reputation, and revenue into a single, measurable framework. Governments and regulators see SMX as the enforcement layer that sustainability has been missing. Brands see it as the technology that transforms compliance from a cost center into a competitive advantage. Investors see a platform with expanding global relevance, capable of tracing not only waste but value itself.

The world has grown skeptical of promises. But proof – measurable, verifiable, permanent proof – has value again. SMX gave it form. It gave it structure. And as headlines from Rolling Stone to USA Today to OPIS make clear, it gave it a future.

Because in the end, progress doesn’t need another promise. It needs proof. And that’s precisely what SMX was built to deliver.

About SMX

As global businesses face new and complex challenges relating to carbon neutrality and meeting new governmental and regional regulations and standards, SMX is able to offer players along the value chain access to its marking, tracking, measuring and digital platform technology to transition more successfully to a low-carbon economy.

Forward-Looking Statements

The information in this press release includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements regarding expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “forecast,” “intends,” “may,” “will,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements in this press release may include, for example: matters relating to the Company’s fight against abusive and possibly illegal trading tactics against the Company’s stock; successful launch and implementation of SMX’s joint projects with manufacturers and other supply chain participants of gold, steel, rubber and other materials; changes in SMX’s strategy, future operations, financial position, estimated revenues and losses, projected costs, prospects and plans; SMX’s ability to develop and launch new products and services, including its planned Plastic Cycle Token; SMX’s ability to successfully and efficiently integrate future expansion plans and opportunities; SMX’s ability to grow its business in a cost-effective manner; SMX’s product development timeline and estimated research and development costs; the implementation, market acceptance and success of SMX’s business model; developments and projections relating to SMX’s competitors and industry; and SMX’s approach and goals with respect to technology. These forward-looking statements are based on information available as of the date of this press release, and current expectations, forecasts and assumptions, and involve a number of judgments, risks and uncertainties. Accordingly, forward-looking statements should not be relied upon as representing views as of any subsequent date, and no obligation is undertaken to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. As a result of a number of known and unknown risks and uncertainties, actual results or performance may be materially different from those expressed or implied by these forward-looking statements. Some factors that could cause actual results to differ include: the ability to maintain the listing of the Company’s shares on Nasdaq; changes in applicable laws or regulations; any lingering effects of the COVID-19 pandemic on SMX’s business; the ability to implement business plans, forecasts, and other expectations, and identify and realize additional opportunities; the risk of downturns and the possibility of rapid change in the highly competitive industry in which SMX operates; the risk that SMX and its current and future collaborators are unable to successfully develop and commercialize SMX’s products or services, or experience significant delays in doing so; the risk that the Company may never achieve or sustain profitability; the risk that the Company will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; the risk that the Company experiences difficulties in managing its growth and expanding operations; the risk that third-party suppliers and manufacturers are not able to fully and timely meet their obligations; the risk that SMX is unable to secure or protect its intellectual property; the possibility that SMX may be adversely affected by other economic, business, and/or competitive factors; and other risks and uncertainties described in SMX’s filings from time to time with the Securities and Exchange Commission.

EMAIL: info@securitymattersltd.com

SOURCE: SMX (Security Matters) Public Limited

View the original press release on ACCESS Newswire

TORONTO, ON / ACCESS Newswire / November 7, 2025 / Eskay Mining Corp. (“Eskay” or the “Company”) (TSXV:ESK)(OTC PINK:ESKYF)(Frankfurt:KN7)(WKN:A0YDPM) is pleased to provide additional assay results from its prospecting and sampling program at its 100% controlled Consolidated Eskay Project (“CEP”) in the Golden Triangle, British Columbia. Over the summer months of 2025, the Company’s geological team systematically prospected and sampled the Vermillion, TM, Red Lightning, and Big Red zones surrounding Unuk Finger Mountain in the southern extent of CEP where high grade gold veins were initially discovered in 2024.

Select Highlights

• This most recent batch of 121 spot rock chip and channel results includes eleven samples assaying over 20 g/t Au and 31 samples assaying over 1 g/t Au.

• The highest grade spot rock chip assays include;

  • 297 g/t Au and 790 g/t Ag collected from a quartz-sulfide vein at TM zone,

  • 217 g/t Au and 0.44% Cu collected from a quartz-sulfide vein at Vermillion zone,

  • 106 g/t Au and 54.9 g/t Ag collected from a quartz-sulfide vein at TM zone, and

  • 65.7 g/t Au, 31.5 g/t Ag, and 0.31% Cucollected from a quartz-sulfide vein at Vermillion zone.

• A channel sample assay at the TM Zone returned 165 g/t Au and 285 g/t Ag over 0.40 m within 45.5 g/t Au and 75.2 g/t Ag over 1.55m.

• A new gold-silver target, the Sultan zone, discovered in the southeastern corner of the claim package returned an initial assay of 11.2 g/t Au and 181 g/t Ag.

“Further expansion of the high-grade vein discovery in the southern portion of our Consolidated Eskay Project now fully explain the robust, large-scale BLEG stream sediment anomaly we identified around Unuk Finger Mountain in recent years,” commented Quinton Hennigh, director and technical advisor to Eskay Mining. “High-grade veins display a pattern of commonly being low-angle and stacked a few tens of meters apart. Veins are comprised of quartz and varying contents of sulfides including base metal sulfides, especially chalcopyrite. We are now seeing broad distribution of these veins, and they appear to display a spatial relation with a nearby Lee Brant Eocene intrusion not unlike those observed at both Goliath Resources’ Surebet project and Juggernaut Exploration’s Big One project. This new target style is generating a lot of excitement in the GT, and we think we may have a similar such exploration target emerging at CEP. We can see a path to inaugural drilling of these veins in 2026.”

2025 Exploration Program

The 2025 field exploration program at the Consolidated Eskay Project included extensive surficial sampling, reconnaissance geological mapping, and channel sampling across target areas around the Unuk Finger Mountain and additional target areas across the property. The focus of the program was to identify and advance early-stage gold-silver prospects into drill ready targets for the 2026 exploration season. All assays have now been received for the 2025 season and this release covers the remaining 95 rock and 26 channel samples collected for a season total of 310 spot rock chip samples and 55 channel samples.

In addition, Worldview 3 high-resolution satellite imagery survey has been collected across the property with results expected later this month. Hyperspectral imaging and detailed orthophotos will help support focused exploration efforts across Eskay’s 200 km² southern target area.

Results from the TM and Vermillion Zones

Exploration conducted across the Vermillion and TM targets has identified significant vein-hosted gold and silver mineralization that share many characteristics with reduced intrusion-related gold systems (RIRGS). Prospecting and reconnaissance mapping have discovered flat lying, sheeted and planar shear quartz vein zones spanning over 600 metres vertically and 500 by 2000 metres laterally with further areas to assess moving forward (Figure 1). Veining is spatially related to a biotite-hornblende quartz monzonite intrusion of the Lee Brant intrusive stock believed to be of Eocene age which covers a 40 sq/km area south of the vein zones.

In-situ visible gold and electrum mineralization have been identified over a 2km strike length occurring in multiple planar and sheeted quartz-carbonate veins at both the Vermillion and TM zone to the east. Veins hosting accessory pyrrhotite, chalcopyrite, bismuthinite, and rarely wolframite and gold show strong correlations with copper, bismuth and silver with anomalous tellurium. Lead and zinc (+/- silver) veins have also been sampled and may represent distal expressions of the mineralizing system. Mineralized veins are primarily hosted in metavolcanic and volcaniclastic sequences of the Lower to Middle Jurassic Hazelton Group and have also been observed in float boulders of the Lee Brant Stock quartz monzonite.

Figure 1. 2025 Sample Location Map and Target Zones of the Eskay Project.

Figure 2. 2025 rock sample assays for gold from TM.

Figure 3. 2025 rock sample assays for gold from Vermillion.

A remaining total of 95 rock sample assays have been received from follow-up sampling at the TM (Figure 2) and Vermillion (Figure 3) zones. Further sampling across the targets has continued to expand upon the surface footprint of vein-hosted gold and silver mineralization and recent sampling has returned the highest gold grades to date in the area with sample A0519920 assaying 297 g/t Au and 790 g/t Ag. Of the 95 rocks collected in the last phase of sampling, 5 rock samples assayed over 20 g/t Au, 8 samples assayed over 10 g/t Au, 14 samples assayed over 5 g/t Au, and 21 samples assayed over 1 g/t Au (Tables 1 and 2).

Select assay highlights from TM & Vermillion include:

• A0519920 assayed 297 g/t Au and 790 g/t Ag

• A0518360 assayed 217 g/t Au and 0.44% Cu

• A0518357 assayed 106 g/t Au and 54.9 g/t Ag

• A0518363 assayed 65.7 g/t Au, 31.5 g/t Ag, and 0.31% Cu

Table 1. Select assay highlights from TM zone rock samples.

Table 2. Select assay highlights from Vermillion zone rock samples.

TM Channel Sample Assay Results

A total of 41.77m of channel sampling has been completed to date at the Vermillion and TM zones. TM channel samples are reported herein, see previous release dated September 17, 2025 for Vermillion channel sample results.

A total of 16.86m across 9 channel series were completed at TM testing various vein generations for gold mineralization (Table 3). Due to terrain limitations channel sampling widths were limited in their extents as the TM area is characterized by steeply sloping topography. Channels were completed at a minimum width of 1.5m to reflect minimum underground mining widths and were sampled both across veins with known gold mineralization as well veins that had not previously been sampled.

All channels were successful in intersecting gold and silver mineralization with significant gold intersections including 165 g/t Au and 285 g/t Ag over 0.40 m within 45.5 g/t Au and 75.2 g/t Ag over 1.55m from Channel V7 and 46.6 g/t Au and 16.7 g/t Ag over 0.25m within 6.67 g/t Au and 2.53 g/t Ag over 1.7m from Channel V4.

Weighted average intervals include:

• Channel V1: 6.11 g/t Au and 5.00 g/t Ag over 1.94m

• Channel V2: 4.17 g/t Au and 4.23 g/t Ag over 1.62m

• Channel V3: 0.18 g/t Au and 0.77 g/t Ag over 2.00m

• Channel V4: 6.67 g/t Au and 2.53 g/t Ag over 1.75m

• Channel V5: 4.96 g/t Au and 6.47 g/t Ag over 2.50m

• Channel V6: 2.99 g/t Au and 2.27 g/t Ag over 2.50m

• Channel V7: 45.5 g/t Au and 75.2 g/t Ag over 1.55m

• Channel V8: 0.15 g/t Au and 0.40 g/t Ag over 1.50m

• Channel V9: 0.49 g/t Au and 1.23 g/t Ag over 1.50m

Table 3. TM Channel Sample Assay Results

Assay Results from the Sultan Zone

One day was spent conducting reconnaissance sampling on previously unexplored areas 7km southeast of the TM Zone at the end of the 2025 season. Prospecting returned promising initial results from base metal veins hosted in broad quartz-sericite-pyrite alteration zones within Upper Triassic rocks of the Stuhini Group with one assay of 11.2 g/t Au and 181 g/t Ag. The recent discovery of additional gold-silver mineralization in the southern extents of the claims support the need for further exploration in the area and attest to the district scale precious and base metal potential across the property.

Figure 4. 2025 rock sample assays for gold from Sultan.

LINK: Click here for complete rock and channel sample assay data.

QA/QC Methodology Statement

Rock chip samples were submitted to MSA Labs in Terrace, British Columbia for preparation and analysis. ALS is accredited to the ISO/IEC 17025 standard for gold assays. All analytical methods include quality control standards inserted at set frequencies. The entire sample interval is crushed and homogenized, 250 g of the homogenized sample is pulped. All samples were analyzed for gold, silver, and a suite of 48 major and trace elements. Analysis for gold is by fire assay fusion followed by Inductively Coupled Plasma Atomic Emission Spectroscopy (ICP-AES) on 30 g of pulp. Analysis for silver is by fire assay and gravimetric analysis on 30 g of pulp. All other major and trace elements are analyzed by four-acid digestion followed by ICP-MS.

Qualified Person

Dr. Quinton Hennigh, P. Geo., a Director of the Company and its technical adviser, a qualified person as defined by National Instrument 43-101, has reviewed and approved the technical contents of this news release.

About Eskay Mining Corp:

Eskay Mining Corp (TSXV:ESK) is a TSX Venture Exchange listed company, headquartered in Toronto, Ontario. Eskay is an exploration company focused on the exploration and development of precious and base metals along the Eskay rift in a highly prolific region of northwest British Columbia known as the “Golden Triangle,” 70km northwest of Stewart, BC. The Company currently holds mineral tenures in this area comprised of 177 claims (52,600 hectares).

All material information on the Company may be found on its website at www.eskaymining.com and on SEDAR+ at www.sedarplus.com.

For further information, please contact:
Mac Balkam
President & Chief Executive Officer
T: 416 907 4020
E: Mac@eskaymining.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements: This Press Release contains forward-looking statements that involve risks and uncertainties, which may cause actual results to differ materially from the statements made. When used in this document, the words “may”, “would”, “could”, “will”, “intend”, “plan”, “anticipate”, “believe”, “estimate”, “expect” and similar expressions are intended to identify forward-looking statements. Such statements reflect our current views with respect to future events and are subject to risks and uncertainties. Many factors could cause our actual results to differ materially from the statements made, including those factors discussed in filings made by us with the Canadian securities regulatory authorities. Should one or more of these risks and uncertainties, such as actual results of current exploration programs, the general risks associated with the mining industry, the price of gold and other metals, currency and interest rate fluctuations, increased competition and general economic and market factors, occur or should assumptions underlying the forward looking statements prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, or expected. We do not intend and do not assume any obligation to update these forward-looking statements, except as required by law. Shareholders are cautioned not to put undue reliance on such forward-looking statements.

SOURCE: Eskay Mining Corp.

View the original press release on ACCESS Newswire

Horizon Aircraft hosted Brigadier General Brendan Cook, RCAF Director General Space, Combat and Support, for a briefing on the Cavorite X7 and its potential Defence applications

LINDSAY, ONTARIO / ACCESS Newswire / November 6, 2025 / New Horizon Aircraft Ltd. (NASDAQ:HOVR), doing business as Horizon Aircraft (“Horizon Aircraft” or the “Company”), an advanced aerospace engineering company and developer of one the world’s first hybrid eVTOL (electric Vertical Take-Off and Landing) aircraft, welcomed Brigadier General Brendan Cook, Royal Canadian Air Force (RCAF) Director General Space, Combat and Support, to its Lindsay, Ontario hangar for an exclusive tour and briefing on the Company’s hybrid eVTOL, the Cavorite X7.

During the visit, BGen Cook met with Horizon Aircraft’s leadership team, toured the facility, and received a detailed demonstration of the Cavorite X7’s hybrid-electric architecture and versatile design.

“I’ve seen some really unique technologies here that I think have a solid position in the Defence market over time,” said BGen Cook. “It’s great to see Canadian innovation and industry putting forward leading-edge aerospace products. From remotely piloted aircraft to vertical lift capabilities, the applications for this technology in the Canadian Armed Forces are wide-ranging, from contested logistics to maritime operations and anti-submarine warfare.”

BGen Cook also noted the potential for NATO collaboration, citing opportunities for Canadian industry to shape and contribute to evolving allied defence requirements.

Horizon Aircraft Co-Founder and CEO, Brandon Robinson, said, “It was an honour to host BGen Cook and share the progress we’ve made with the Cavorite X7. His visit underscores the growing recognition of Canadian aerospace innovation, and we believe our technology is well positioned for future defence applications in Canada and with our allies worldwide.”

The Cavorite X7 has been engineered with defence and dual-use applications in mind, offering potential roles in:

• Contested logistics and cargo delivery;

• Medical evacuation (MEDEVAC) and covert insertion;

• Remotely Piloted Aircraft Systems (RPAS) and loyal wingman missions; and

• Advanced surveillance and electronic power support, enabled by its onboard hybrid electrical capacity.

With the Cavorite X7, Horizon Aircraft continues to position Canada as a leader in aerospace technology, advancing solutions that align with the modern defence needs of the Canadian Armed Forces and allied partners.

For more information about Horizon Aircraft, please see the Company’s website or watch its innovative technology in action on the Company’s YouTube channel.

About Horizon Aircraft

Horizon Aircraft (NASDAQ: HOVR) is an advanced aerospace engineering company that is developing one of the world’s first hybrid eVTOL designed to fly most of its mission exactly like a normal aircraft while offering industry-leading speed, range, and operational utility. Horizon Aircraft’s unique designs put the mission first and prioritize safety, performance, and utility. Horizon Aircraft intends to successfully complete testing and certification of its Cavorite X7 eVTOL and then scale unit production to meet expected demand from regional operators, emergency service providers, and military customers.

For further information, visit:

Website www.horizonaircraft.com
LinkedIn https://www.linkedin.com/company/horizon-aircraft-inc

For further information, contact:

Investors:
Matt Chesler, CFA
FNK IR LLC
(646) 809-2183
HOVR@fnkir.com

Media:
Edwina Frawley-Gangahar
EFG Media Relations
+44 7580 174672
edwina@efgmediarelations.com

Forward-Looking Statements

This press release contains certain “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and “forward-looking information” within the meaning of applicable Canadian securities laws (collectively, “forward-looking statements”). These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “aim,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “target,” “will be,” “will continue,” “will likely result” and similar expressions, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements herein include, but are not limited to, statements relating to the targeted readiness of the full-scale hybrid Cavorite X7 eVTOL prototype for initial testing, development priorities and technical milestones; funding and liquidity sufficiency and runway; certification and testing plans; and potential production, partnership, supply chain and market opportunities.

Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Actual results may differ from their expectations, estimates and projections and consequently, you should not rely on these forward-looking statements as predictions of future events. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to: (i) changes in the markets in which Horizon Aircraft competes, including with respect to its competitive landscape, technology evolution or regulatory changes; (ii) the risk that Horizon Aircraft will need to raise additional capital to execute its business plans, which may not be available on acceptable terms or at all; (iii) the lack of useful financial information for an accurate estimate of future capital expenditures and future revenue; (iv) statements regarding Horizon Aircraft’s industry and market size; (v) financial condition and performance of Horizon Aircraft, including the condition, liquidity, results of operations, the products, the expected future performance and market opportunities of Horizon Aircraft; (vi) Horizon Aircraft’s ability to develop, certify, and manufacture an aircraft that meets its performance expectations; (vii) successful completion of testing and certification of Horizon Aircraft’s Cavorite X7 eVTOL; (viii) the targeted future production of Horizon Aircraft’s Cavorite X7 aircraft; and (ix) other factors detailed by us in the Company’s public filings with the Securities and Exchange Commission (“SEC”) and under the Company’s profile on sedarplus.ca, including the disclosures under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the fiscal year ended May 31, 2025, filed with the SEC and filed under the Company’s profile on sedarplus.ca on August 22, 2025. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made.

Readers are cautioned not to put undue reliance on forward-looking statements, and while the Company may elect to update these forward-looking statements at some point in the future, it assumes no obligation to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise, unless required by applicable law. Horizon Aircraft does not give any assurance that Horizon Aircraft will achieve its expectations.

SOURCE: Horizon Aircraft

View the original press release on ACCESS Newswire

Company reaffirms its commitment to patient access, clinical excellence, and responsible reimbursement reform under the new CMS framework.

MISSOULA, MT / ACCESS Newswire / November 6, 2025 / Venture Medical, LLC, today issued the following statement regarding the Centers for Medicare & Medicaid Services’ (CMS) Calendar Year 2026 Physician Fee Schedule (PFS) Final Rule, which introduces a new framework for the Medicare reimbursement of skin substitutes.

“CMS’s final rule represents a defining moment for the wound care industry,” said John Schroeder, CEO of Venture Medical. “As one of the nation’s leading distributors of advanced wound care solutions, we’ve long advocated for clarity and consistency in coverage and reimbursement – ensuring that providers can focus on what matters most: delivering outcomes-driven care to their patients. Unfortunately, the $127 PFS rate will severely compromise access to therapies and specialized wound care in general. The intersection of this rate with the overly restrictive covered list of products in the January 1 2026 effective LCDs will exacerbate devastating complications for patients. Adding to these, the apparently weaponized posture recently embraced by auditors could severely backfire for an administration we believe has the best of intentions for our elderly and vulnerable patients. We will accelerate our work with committed industry colleagues, CMS, policymakers, and key opinion leaders to improve reimbursement and access to skin substitutes, as this threat to patient care must be alleviated.”

The new reimbursement structure reflects CMS’s intent to foster a more balanced, evidence-based market – one that rewards quality, compliance, and clinical performance. Venture Medical remains fully aligned with this mission. Through its partnerships with industry innovators like BioStem Technologies, Inc. and its distribution of clinically validated allografts including VENDAJE AC®, and AmnioWrap2™ along with a curated, end-to-end portfolio of advanced wound care products including offloading devices, compression therapies, advanced dressings, debridement tools, anti-biofilm strategies, and advanced imaging, Venture Medical continues to prioritize access to cutting-edge technologies supported by science and real-world results.

“While change always brings challenges, our role is to lead with preparation and confidence,” added Schroeder. “Venture has proactively developed strategies to help our customers navigate these updates – offering education, policy guidance, and product solutions along with efficient practice solutions that meet both clinical and economic demands. We are positioned to take a bold approach and lead further change in this new season of wound care.”

As the market transitions to this new era of standardized reimbursement, Venture Medical remains steadfast in its commitment to advocacy, innovation, and partnership – helping clinicians deliver the highest level of patient care while sustaining operational excellence in a changing landscape.

SOURCE: Venture Medical LLC

View the original press release on ACCESS Newswire

Reports third quarter revenue of $1.0 billion, GAAP net loss of $(0.2) billion and GAAP EPS of $(0.51)

Narrows 2025 projected revenue range to $1.6 – $2.0 billion

Improves 2025 expected GAAP operating expenses by $0.7 billion to a range of $5.2 – $5.4 billion

Increases 2025 expected year-end cash balance by $0.5 billion – $1 billion to a range of $6.5 – $7.0 billion

CAMBRIDGE, MA / ACCESS Newswire / November 6, 2025 / Moderna, Inc. (NASDAQ:MRNA) today reported financial results and provided business updates for the third quarter of 2025.

“We delivered strong commercial and financial performance in the third quarter, supported by COVID vaccine sales following the successful launch of mNEXSPIKE and a significant improvement in expected 2025 operating expenses from our ongoing cost-reduction initiatives,” said Stéphane Bancel, Chief Executive Officer of Moderna. “We remain highly focused on operational excellence and financial discipline to advance our pipeline and expand the reach of our commercial portfolio. We look forward to sharing further updates on our business and pipeline at our annual Analyst Day on November 20.”

Recent progress includes:

Commercial Updates

COVID–19: The Company reported $971 million in COVID vaccine sales in the third quarter of 2025, which includes $781 million of U.S. sales and $190 million of international sales. The Company has received approval in 40 countries of its 2025-2026 formula for Spikevax®. Moderna has also received U.S. Food and Drug Administration (FDA) approval of its 2025-2026 formula for mNEXSPIKE®, the Company’s new COVID vaccine in all adults aged 65 and older, as well as individuals aged 12-64 years with at least one underlying risk factor. mNEXSPIKE is also approved in Canada and the Company has filed and is targeting 2026 approvals in Australia, the EU, Japan and Taiwan.

RSV: The Company reported $2 million in mRESVIA® sales in the third quarter of 2025. mRESVIA, the Company’s vaccine for the prevention of lower respiratory tract disease (LRTD) caused by RSV, is approved for all adults aged 60 years and older in 40 countries. It is also approved in 31 of those countries for individuals 18-59 years of age who are at increased risk for disease.

Third Quarter 2025 Financial Results

Revenue: Total revenue for the third quarter of 2025 was $1.0 billion, a 45% decrease from $1.9 billion in the same period in 2024. The decline was primarily driven by a $847 million, or 47%, decrease in net product sales, mainly due to lower COVID vaccine sales. In the U.S., the decrease reflected reduced vaccination rates year over year. The third quarter of 2024 also included an approximately $140 million positive adjustment related to prior-period sales provision estimates, which did not recur in 2025. During the quarter, the Company initiated commercial sales in the U.S. of mNEXSPIKE, as part of the 2025-2026 respiratory virus season.Outside the U.S., revenue decreased primarily due to the completion of certain government contracts and the timing of deliveries.

Cost of Sales: Cost of sales for the third quarter of 2025 was $207 million, which included third-party royalties of $43 million and inventory write-downs of $67 million. Cost of sales decreased 60% compared to the same period in 2024, primarily reflecting lower inventory write-downs and reduced unutilized manufacturing capacity, as well as lower sales volume. As a percentage of net product sales, cost of sales was 21% compared to 28% in the third quarter of 2024. The improvement was mainly driven by productivity gains and efficiencies across manufacturing operations despite lower volumes.

Research and Development Expenses: Research and development expenses for the third quarter of 2025 were $801 million, a 30% decrease compared to the same period in 2024. The reduction was primarily driven by continued investment prioritization and efficiency gains in the execution of clinical trials. Last year’s results also included an expense related to the purchase of a priority review voucher.

Selling, General and Administrative Expenses: Selling, general and administrative expenses for the third quarter of 2025 were $268 million, a 5% decrease compared to the same period in 2024. The decline was primarily driven by reductions in consulting and external services across multiple functions, as well as lower digital and facility-related costs, reflecting the Company’s continued cost discipline and ongoing efforts to streamline operations.

Income Taxes: Income tax provisions for both periods were not material, as the Company continues to maintain a global valuation allowance against most of its deferred tax assets.

Net Income (Loss): Net loss was $(200) million for the third quarter of 2025, compared to net income of $13 million for the third quarter of 2024.

Earnings (Loss) Per Share: Loss per share was $(0.51) for the third quarter of 2025, compared to earnings per share of $0.03 for the third quarter of 2024.

Cash Position: Cash, cash equivalents and investments as of September 30, 2025, were $6.6 billion, compared to $7.5 billion as of June 30, 2025. The decrease during the quarter was primarily driven by seasonal impacts on working capital.

2025 Financial Framework

Revenue: The Company narrowed its 2025 projected revenue range from $1.5 to $2.2 billion to $1.6 to $2.0 billion, reflecting third quarter results and expectations for the remainder of the year.

Cost of Sales: Cost of sales for 2025 is expected to be approximately $0.8 to $0.9 billion, lowered from $1.2 billion.

Research and Development Expenses: Research and development expenses for 2025 are anticipated to be $3.3 to $3.4 billion, lowered from previous expectations of $3.6 to $3.8 billion.

Selling, General and Administrative Expenses: Selling, general and administrative expenses for 2025 are projected to be approximately $1.1 billion.

Income Taxes: The Company continues to expect its full-year tax expense to be negligible.

Capital Expenditures: Capital expenditures for 2025 are expected to be approximately $0.3 billion.

Cash and Investments: Year-end cash and investments for 2025 are projected to be $6.5 to $7 billion, increased from previous expectations of approximately $6 billion.

Recent Progress and Upcoming Late-Stage Pipeline Milestones

Respiratory vaccines:

• Seasonal flu vaccine: In October 2025, Moderna presented Phase 3 efficacy and safety data for its seasonal flu vaccine (mRNA-1010) at IDWeek 2025, and Phase 3 relative vaccine efficacy in a high-risk subset of patients at The European Scientific Working Group on Influenza (ESWI) Conference 2025. The Company expects to complete submissions for approval of mRNA-1010 in the U.S., Canada, Australia and Europe by January 2026.

• Seasonal flu + COVID vaccine: The Company presented Phase 3 immunogenicity subanalyses for its flu/COVID combination vaccine (mRNA-1083) for adults aged 50 years and older at ESWI 2025. The Company expects to refile with Health Canada in 2025 and is awaiting further guidance from U.S. FDA on refiling. Currently, the Company’s mRNA-1083 filing is under review with the European Medicines Agency (EMA).

Latent and other vaccines:

• Norovirus vaccine: Moderna’s ongoing Phase 3 safety and efficacy study of its trivalent vaccine against norovirus (mRNA-1403) has not accrued sufficient cases and will now enroll a second Northern Hemisphere season (2025-2026) for additional case accruals. The timing of the Phase 3 readout will continue to be dependent on case accruals.

• Cytomegalovirus (CMV) vaccine: After announcing that the Phase 3 study of mRNA-1647 did not meet its primary efficacy endpoint, Moderna is discontinuing development of its congenital CMV program. The Company will continue to evaluate mRNA-1647 in an ongoing Phase 2 trial of bone marrow transplant patients.

Oncology therapeutics:

• Intismeran autogene: Moderna continues to make progress on advancing mRNA-4157 in the clinic.In collaboration with Merck, the Phase 3 clinical trial for adjuvant melanoma is fully enrolled. Two non-small cell lung cancer (NSCLC) Phase 3 studies for those with and without prior neoadjuvant treatment are enrolling. Separate randomized Phase 2 studies for high-risk muscle invasive and high-risk non-muscle invasive bladder cancer are enrolling, a Phase 2 study of first-line treatment for patients with metastatic melanoma is also enrolling, and a randomized Phase 2 study for adjuvant renal cell carcinoma is fully enrolled. Further, Moderna and Merck have launched a new Phase 2 study of first-line treatment for patients with metastatic squamous NSCLC.

• mRNA-4359: The Phase 1/2 study of mRNA-4359, Moderna’s investigational mRNA-based therapy designed to elicit T-cell immune responses against tumor and immunosuppressive cells, is ongoing. Phase 1b data for mRNA-4359 was recently presented at the 2025 European Society for Medical Oncology (ESMO) Congress. The Phase 2 portion of the study, which includes cohorts in first-line metastatic melanoma and first-line metastatic NSCLC, is enrolling patients.

Rare disease therapeutics:

• Propionic acidemia (PA) therapeutic: The Company recently presented final results from the Part 1 dose-escalation cohorts of its ongoing Phase 1/2 study and cumulative data from ongoing participants in the extension study of its investigational therapeutic for PA (mRNA-3927) at the International Congress of Inborn Errors of Metabolism (ICIEM) 2025. In the study, which is designed to evaluate safety and pharmacology in trial participants with PA, mRNA-3927 has been generally well-tolerated to date with no events meeting protocol-defined dose-limiting toxicity criteria. Previously presented results suggest potential decreases in annualized metabolic decompensation event (MDE) frequency compared to pre-treatment, and the majority of patients have elected to continue on the open label extension study. The Company’s PA candidate is in a registrational study and target enrollment has been reached.

• Methylmalonic acidemia (MMA) therapeutic: Moderna recently shared interim data from the Phase 1/2 study of its investigational therapeutic for MMA (mRNA-3705) at ICIEM 2025. mRNA-3705 has been selected by the FDA for the Support for Clinical Trials Advancing Rare Disease Therapeutics (START) pilot program, and the FDA and Moderna have agreed on the pivotal study design. The Company expects to start a registrational study in 2026.

Moderna Corporate Updates

• The Company opened its state-of-the-art manufacturing and R&D facility in the UK, which is now licensed by the Medicines and Healthcare products Regulatory Agency (MHRA)

• Moderna announced the first made-in-Canada mRNA vaccines were delivered to Canadian provinces and territories

• The Company’s manufacturing facility in Australia was recently granted its Good Manufacturing Practice (GMP) license from the Therapeutic Goods Administration (TGA)

Company Accolades

• Moderna was recognized on BioSpace‘s Best Places to Work in Biopharma ranking of large employers (fifth consecutive year)

• Moderna was ranked as a top employer in the global biopharmaceutical industry by Science on the Science Careers’ 2025 Top Employers Survey (eleventh consecutive year)

Key 2025 Investor and Analyst Event Dates

• Analyst Day: November 20

Investor Call and Webcast Information

Moderna will host a live conference call and webcast at 8:00 a.m. ET on November 6, 2025. To access the live conference call via telephone, please register at the link below. Once registered, dial-in numbers and a unique pin number will be provided. A live webcast of the call will also be available under “Events and Presentations” in the Investors section of the Moderna website.

• Telephone: https://register-conf.media-server.com/register/BIc5ea89c0e58143c29f38efc11c3bccc4

• Webcast: https://investors.modernatx.com/

The archived webcast will be available on Moderna’s website approximately two hours after the conference call and will be available for one year following the call.

About Moderna

Moderna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent disease for everyone. By working at the intersection of science, technology and health for more than a decade, the company has developed medicines at unprecedented speed and efficiency, including one of the earliest and most effective COVID vaccines.

Moderna’s mRNA platform has enabled the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. With a unique culture and a global team driven by the Moderna values and mindsets to responsibly change the future of human health, Moderna strives to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit modernatx.com and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn.

MODERNA, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited, in millions, except per share data)

_______

¹Includes grant, collaboration, licensing and royalty, and other miscellaneous revenue.

MODERNA, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(Unaudited, in millions)

MODERNA, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited, in millions)

Spikevax®, mRESVIA® and mNEXSPIKE® are registered trademarks of Moderna.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding: Moderna’s 2025 financial framework, including its expected revenue range, operating expenses and year-end cash balance; demand for Moderna’s products and Moderna’s ability to drive future sales growth; Moderna’s continued cost discipline; anticipated regulatory filings and potential approvals; and anticipated milestones for Moderna’s pipeline programs, including potential near-term catalysts. In some cases, forward-looking statements can be identified by terminology such as “will,” “may,” “should,” “could,” “expects,” “intends,” “plans,” “aims,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “continue,” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna’s control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include, among others, those risks and uncertainties described under the heading “Risk Factors” in Moderna’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the U.S. Securities and Exchange Commission (SEC), and in subsequent filings made by Moderna with the SEC, which are available on the SEC’s website at www.sec.gov. Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna’s current expectations and speak only as of the date of this press release.

###

Moderna Contacts
Media:
Chris Ridley
Head of Global Media Relations
+1 617-800-3651
Chris.Ridley@modernatx.com

Investors:
Lavina Talukdar
Senior Vice President & Head of Investor Relations
+1 617-209-5834
Lavina.Talukdar@modernatx.com

SOURCE: Moderna, Inc.

View the original press release on ACCESS Newswire

MELVILLE, NY AND DAVIDSON, NC / ACCESS Newswire / November 6, 2025 / MSC Industrial Supply Co. (NYSE:MSM), a premier distributor of Metalworking and Maintenance, Repair and Operations (MRO) products and services to industrial customers throughout North America, today announced the following upcoming investor events:

A real-time audio webcast of both fireside chats can be accessed via the Events and Presentations section of MSC Industrial Supply Co. Investor Relations website at https://investor.mscdirect.com/events-presentations. A replay of the webcasts will be available after the conclusion of each fireside chat and can be accessed on the MSC Industrial Supply Co. Investor Relations website.

# # #

About MSC Industrial Supply Co.

MSC Industrial Supply Co. (NYSE:MSM) is a leading North American distributor of a broad range of metalworking and maintenance, repair and operations (MRO) products and services. We help our customers drive greater productivity, profitability and growth with approximately 2.5 million products, inventory management and other supply chain solutions, and deep expertise from more than 80 years of working with customers across industries. Our experienced team of more than 7,000 associates works with our customers to help drive results for their businesses – from keeping operations running efficiently today to continuously rethinking, retooling and optimizing for a more productive tomorrow. For more information on MSC Industrial, please visit mscdirect.com.

Cautionary Note Regarding Forward-Looking Statements

Statements in this press release may constitute “forward-looking statements” under the Private Securities Litigation Reform Act of 1995. All statements, other than statements of present or historical fact, that address activities, events or developments that MSC expects, believes or anticipates will or may occur in the future, including statements about results of operations and financial condition, expected future results, expected benefits from our investment and strategic plans and other initiatives, and expected future growth and profitability, are forward-looking statements. The words “will,” “may,” “believes,” “anticipates,” “thinks,” “expects,” “estimates,” “plans,” “intends” and similar expressions are intended to identify forward-looking statements. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those anticipated by these forward-looking statements. In addition, statements which refer to expectations, projections or other characterizations of future events or circumstances, statements involving a discussion of strategy, plans or intentions, statements about management’s assumptions, projections or predictions of future events or market outlook and any other statement other than a statement of present or historical fact are forward-looking statements. The inclusion of any statement in this press release does not constitute an admission by MSC or any other person that the events or circumstances described in such statement are material. In addition, new risks may emerge from time to time and it is not possible for management to predict such risks or to assess the impact of such risks on our business or financial results. Accordingly, future results may differ materially from historical results or from those discussed or implied by these forward-looking statements. Given these risks and uncertainties, the reader should not place undue reliance on these forward-looking statements. These risks and uncertainties include, but are not limited to, the following: general economic conditions in the markets in which we operate; changing customer and product mixes; volatility in commodity, energy and labor prices, and the impact of prolonged periods of low, high or rapid inflation; competition, including the adoption by competitors of aggressive pricing strategies or sales methods; industry consolidation and other changes in the industrial distribution sector; the applicability of laws and regulations relating to our status as a supplier to the U.S. government and public sector; the credit risk of our customers; our ability to accurately forecast customer demands; interruptions in our ability to make deliveries to customers; supply chain disruptions; our ability to attract and retain sales and customer service personnel; the risk of loss of key suppliers or contractors or key brands; changes to trade policies or trade relationships, including tariff policies; risks associated with opening or expanding our customer fulfillment centers; our ability to estimate the cost of healthcare claims incurred under our self-insurance plan; interruption of operations at our headquarters or customer fulfillment centers; products liability due to the nature of the products that we sell; impairments of goodwill and other indefinite-lived intangible assets; the impact of climate change; operating and financial restrictions imposed by the terms of our material debt instruments; our ability to access additional liquidity; the significant influence that our principal shareholders will continue to have over our decisions; our ability to execute on our E-commerce strategies and maintain our digital platforms; costs associated with maintaining our information technology (“IT”) systems and complying with data privacy laws; disruptions or breaches of our IT systems or violations of data privacy laws, including such disruptions or breaches in connection with our E-commerce channels; risks related to online payment methods and other online transactions; our ability to remediate a material weakness in our internal control over financial reporting and to maintain effective internal control over financial reporting and our disclosure controls and procedures in the future; the retention of key management personnel; litigation risk due to the nature of our business; failure to comply with environmental, health, and safety laws and regulations; and our ability to comply with, and the costs associated with, social and environmental responsibility policies. Additional information concerning these and other risks is described under “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual and Quarterly Reports on Forms 10-K and 10-Q, respectively, and in the other reports and documents that we file with the United States Securities and Exchange Commission. We expressly disclaim any obligation to update any of these forward-looking statements, except to the extent required by applicable law.

SOURCE: MSC Industrial Direct Co.

View the original press release on ACCESS Newswire